ClinicalTrials.gg
Sign In
DrugBiological

Montanide ISA 51 VG clinical trials

studies test it
7
open now
0
in phase 3
0
first study started
1999

How each study uses Montanide ISA 51 VG is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Montanide ISA 51 VG
4

In one entry with another drug

Given together, or one or the other

P10s-PADRE/ MONTANIDE™ ISA 51 VG
2

Studies by the year they started

7 studies that test it; most in 1999 (1)

Studies that test Montanide ISA 51 VG, by start year
YearStudies
19991
20041
20111
20151
20191
20231
20241

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
5
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Uveal Melanoma
1
Anemia, Refractory, with Excess of Blasts
1
Esophageal Neoplasms
1

Who runs them

Industry 0 · Other 7

University of Arkansas (2) · National Cancer Institute (NCI) (2) · University of Chicago (1) · University of Southern California (1) · University of Oxford (1)

Often tested with

Tested in the same studies.

Mimotope-P10s-PADRE Peptide Vaccine (2) · Poly ICLC (1) · Incomplete Freund's adjuvant (1) · Keyhole limpet hemocyanin (1) · Aluminum Hydroxide (1) · Entinostat (1)

Studies

Open first, then newest update. How each study uses Montanide ISA 51 VG is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Given beside what is tested · 9 — Montanide ISA 51 VG is usual care or a partner of the new treatment